The Global Initiative for Asthma (GINA) guidelines provide evidence-based recommendations for the management of asthma. The latest edition, released in 2024, includes the following key points:
Diagnosis and Assessment:
Confirm asthma diagnosis with spirometry.
Assess asthma control using the GINA Asthma Control Questionnaire (ACQ-5).
Identify risk factors for exacerbations, such as smoking, obesity, and poor inhaler technique.
Treatment:
All patients with asthma should receive inhaled corticosteroids (ICS) as maintenance therapy.
For mild asthma, as-needed ICS with short-acting beta-agonists (SABAs) is recommended.
For moderate-to-severe asthma, add-on therapies such as long-acting beta-agonists (LABAs), tiotropium, or biologics may be necessary.
Consider using single-inhaler combination therapies (ICS-LABA) for convenience and adherence.
Monitoring and Management:
Regularly review asthma control and adjust treatment as needed.
Encourage patients to use inhalers correctly and adhere to medication regimens.
Monitor for side effects of asthma medications.
Provide education on asthma self-management, including triggers, avoidance strategies, and emergency action plans.
Specific Recommendations:
For patients with severe asthma, consider using high-dose ICS-LABA or biologics.
For patients with difficult-to-treat asthma, refer to a specialist.
For pregnant women with asthma, individualized treatment plans are essential.
Please note that these guidelines are general recommendations and may vary depending on the individual patient's circumstances. It is important to consult with a healthcare professional for